Poolbeg Pharma has secured a South African patent covering the use of its investigational therapy POLB 001 for the prevention of hypercytokinaemia and severe influenza.

The patent provides intellectual property protection until December 2038 and expands the company’s patent portfolio for the p38 MAP kinase inhibitor.

POLB 001 is being developed across multiple indications, including the prevention of cytokine release syndrome associated with cancer immunotherapy and severe influenza.

According to Poolbeg, the new patent strengthens its existing intellectual property covering p38 MAP kinase inhibitors for severe influenza and hypercytokinaemia, while additional patent applications have been filed relating to cancer immunotherapy-induced cytokine release syndrome.

Jeremy Skillington, chief executive officer of Poolbeg Pharma, said: “This latest patent grant reflects our commitment to further strengthen POLB 001’s global IP portfolio, enhancing its value and attractiveness to prospective partners.”

He added: “POLB 001 holds the potential to significantly benefit patients and healthcare systems globally across multiple disease areas, and this patent represents another step forward in our mission to positively impact the lives of patients.”

The company said developing its intellectual property estate remains a priority as it advances POLB 001 and seeks future commercial partnerships.

SEO tags: Poolbeg Pharma, POLB 001, South Africa patent, cytokine release syndrome, CRS, severe influenza, p38 MAP kinase inhibitor, intellectual property

Pic suggestion: Poolbeg Pharma logo or a laboratory researcher.

Short slug: poolbeg-polb001-south-africa-patent